title: [Study of 206 transfused sickle cell disease patients: immunization, transfusion safety and red blood cell supply].
abstract: BACKGROUND
  Prevention of hemolytic transfusion reactions depends upon our capacity to prevent allo-immunization and conflicts between antigens of transfused red blood cells and antibodies produced by the recipient. In this study, we show that to secure transfusion of sickle cell disease patients, it is necessary to take into account their immunohematologic characteristics in the organization of transfusion.
  
  
  RESULTS
  Immunohematological data of 206 chronically transfused patients have been collected as well as phenotypes of transfused units. In order to prevent allo-immunization against C and E antigens for patients typed D+C-E-c+e+ (56%), 26% of the transfused units were D-C-E-c+e+. We found that 47% of the patients had a history of allo-immunization, whereas only 15% produced an antibody the day of inclusion in the study. The non-detectable antibodies were frequently known as dangerous for transfusion. Finally, this study shows the frequency of anti-D in D+ patients and anti-C in C+ patients, pointing out the question of partial antigens.
  
  
  CONCLUSIONS
  To insure optimal transfusion safety for sickle cell disease patients, three points have to be improved: blood donation within the Afro-Caribbean community living in France, access to history of immuno-hematological data, detection of variant antigens, especially within the RH blood system.
authors.affiliation: Etablissement français du sang d'Ile-de-France, site Henri-Mondor, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
authors.forename: N
authors.initials: N
authors.lastname: Meunier
authors.forename: M
authors.initials: M
authors.lastname: Rodet
authors.forename: P
authors.initials: P
authors.lastname: Bonin
authors.forename: P
authors.initials: P
authors.lastname: Chadebech
authors.forename: B
authors.initials: B
authors.lastname: Chami
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Habibi
authors.forename: D
authors.initials: D
authors.lastname: Bachir
authors.forename: F
authors.initials: F
authors.lastname: Galactéros
authors.forename: P
authors.initials: P
authors.lastname: Bierling
authors.forename: F
authors.initials: F
authors.lastname: Noizat-Pirenne
mesh_terms: D000017:ABO Blood-Group System; D000755:Anemia, Sickle Cell / Q000276:immunology / Q000628:therapy*; D000917:Antibody Formation; D001787:Blood Group Incompatibility / Q000517:prevention & control; D001803:Blood Transfusion / Q000592:standards*; D006801:Humans; D007114:Immunization; D007518:Isoantibodies / Q000097:blood; D012204:Rh-Hr Blood-Group System / Q000276:immunology; D012449:Safety; D065227:Transfusion Reaction
chemical_list: D000017:ABO Blood-Group System; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System